Core Viewpoint - Glucotrack, Inc. is making significant advancements in the development of its fully implantable continuous blood glucose monitor (CBGM) system, with plans to initiate clinical studies in Australia and submit an Investigational Device Exemption (IDE) to the FDA by the end of 2025, while also strengthening its corporate structure and expanding its advisory boards [1][2][11]. Corporate Highlights - The company is on track to implant the first patients in a long-term, multicenter feasibility study of the CBGM system in Australia in Q3 2025 [1]. - An IDE submission to the FDA for the novel CBGM technology is anticipated in Q4 2025 [1]. - The Board of Directors has been strengthened with the appointment of Dr. David S. Hirsh as Medical Director - Cardiology and Dr. Victoria E. Carr-Brendel to the Board [2][5]. - A Patient Advisory Board has been established to incorporate patient perspectives into the development of the CBGM technology [2][5]. Financial Overview - Cash and cash equivalents as of June 30, 2025, were $9.6 million, an increase from $5.6 million as of December 31, 2024, primarily due to $10.7 million in net proceeds from public equity financings [12]. - Research and development expenses for the six months ended June 30, 2025, were $5.0 million, down from $5.7 million in the prior-year period [8]. - Marketing, general, and administrative expenses increased to $3.3 million for the six months ended June 30, 2025, compared to $1.7 million in the prior-year period [9]. - The net loss for the six months ended June 30, 2025, was $11.6 million, compared to a net loss of $7.4 million for the same period in the previous year [10]. Clinical Development - Positive results were reported from a first-in-human study for the CBGM, achieving a Mean Absolute Relative Difference (MARD) of 7.7% across 122 matched pairs, with a 99% data capture rate [11]. - The company received ethical approval in Australia to initiate a long-term clinical study of the CBGM in participants with type 1 and type 2 diabetes [11]. - Glucotrack is participating in the FORGETDIABETES initiative, which aims to develop an artificial pancreas for type 1 diabetes, utilizing the CBGM technology for real-time glucose data [11].

Core Viewpoint - Intchains Group Limited has reported a significant increase in its Ethereum (ETH) holdings and has adopted a long-term dollar-cost averaging strategy to enhance yield performance while navigating market volatility [1][5][9]. Financial Highlights - Revenue for Q2 2025 was RMB 43.2 million (US$ 6.0 million), a decrease of 64.9% from RMB 123.0 million in Q2 2024, primarily due to cyclical fluctuations and lower demand for mining machines [12][17]. - For H1 2025, revenue increased by 19.2% to RMB 175.6 million (US$ 24.5 million) compared to RMB 147.3 million in H1 2024, driven by strong sales of altcoin mining products [28]. - The company reported a net income of RMB 38.3 million (US$ 5.3 million) for Q2 2025, down 24% from RMB 50.4 million in Q2 2024 [24]. Operational Highlights - The company increased its ETH holdings to 8,816 ETH as of June 30, 2025, up 26% from March 31, 2025, and 55% from December 31, 2024 [1][9]. - The company has invested approximately RMB 41.6 million in R&D for new mining machines and upgrades since the beginning of 2025 [28]. - New product launches include the Aleo Mining Series and Goldshell Byte, which are designed to enhance competitiveness in the mining sector [28]. Strategic Focus - The company is committed to a long-term dollar-cost averaging strategy for ETH, which aims to build a digital asset reserve while mitigating short-term market volatility [5][8]. - Future strategies include expanding ETH reserves and launching yield-generating initiatives with FalconX to improve profitability [6][11]. - The company anticipates that these strategic moves will lead to tangible growth in 2026, capturing market share in the next altcoin cycle [7]. Cryptocurrency Management - The fair value of the company's cryptocurrency assets, excluding stablecoins, was RMB 157.7 million, primarily consisting of approximately 8,816 ETH valued at RMB 157.4 million (US$ 22.0 million) [12]. - The company plans to deploy a portion of its ETH holdings into yield-generating activities, including staking and liquidity provisioning [10]. Market Position - Intchains Group Limited has been identified as one of the top ETH treasury holders among public companies globally, reflecting its strategic focus on digital asset management [12][28].

Core Insights - Bolt Biotherapeutics is advancing its clinical-stage immunotherapy pipeline, particularly focusing on BDC-4182, a next-generation Boltbody™ ISAC targeting claudin 18.2, currently in a Phase 1 dose-escalation study for gastric and gastroesophageal cancer [2][6][9] - The company reported a cash balance of $48.5 million as of June 30, 2025, which is expected to fund key milestones through mid-2026 [5][6] - Collaboration revenue for the second quarter of 2025 was $1.8 million, an increase from $1.3 million in the same quarter of 2024, indicating growth in R&D collaborations [6][11] Business Update - The Phase 1 study for BDC-4182 opened for enrollment in early 2025, with initial data expected in the first half of 2026 [2][6] - The company is seeking a partner for the further development of BDC-3042, which has shown activity in lung cancer patients [2][6] - Collaborations with Genmab and Toray are progressing, focusing on multiple development candidates and research programs [6][9] Financial Results - Total collaboration revenue for the quarter ended June 30, 2025, was $1.8 million, compared to $1.3 million for the same quarter in 2024 [6][11] - Research and Development (R&D) expenses decreased to $7.5 million in Q2 2025 from $15.4 million in Q2 2024, primarily due to reduced salary and clinical expenses [6][11] - General and Administrative (G&A) expenses also decreased to $3.5 million in Q2 2025 from $4.9 million in Q2 2024, reflecting cost management efforts [6][11] Operational Highlights - The company executed a one-for-twenty reverse stock split on June 6, 2025, which helped regain compliance with Nasdaq's minimum bid price requirement [7] - The Boltbody™ ISAC platform combines tumor-targeting antibodies with immune stimulants to enhance anti-cancer responses [8][9] - The company’s pipeline includes BDC-4182 and BDC-3042, with ongoing efforts to establish partnerships for further development [9]

Core Insights - Fortress Biotech, Inc. achieved significant milestones in Q2 2025, including the acquisition of its subsidiary Checkpoint Therapeutics by Sun Pharma, which provided approximately $28 million upfront and potential additional payments [2][3] - The FDA accepted the New Drug Application for CUTX-101 for Menkes disease, with a PDUFA goal date set for September 30, 2025 [2][6] - Journey Medical launched Emrosi™ for treating inflammatory lesions of rosacea, with commercial uptake expanding to cover 65% of U.S. commercial lives [2][5] Financial Performance - Fortress reported consolidated net revenue of $16.4 million for Q2 2025, an increase from $14.9 million in Q2 2024, primarily driven by dermatology product sales [11][18] - Consolidated cash and cash equivalents rose to $74.4 million as of June 30, 2025, up from $57.3 million at the end of 2024 [11][16] - The company recorded a net income attributable to common stockholders of $13.4 million, or $0.50 per share basic, compared to a net loss of $(13.3) million in the same quarter of the previous year [11][18] Regulatory Developments - The FDA granted Orphan Drug Designation to Mustang Bio for MB-101, enhancing the potential of the combination strategy with MB-108 for treating high-grade gliomas [6][12] - The NDA submission for CUTX-101 is under priority review, with expectations for a Priority Review Voucher upon approval [2][6] Commercial Updates - Journey Medical's Emrosi™ has seen expanded payer access, now covering over 100 million commercial lives in the U.S., up from 54 million in May 2025 [10][12] - The commercial launch of Emrosi™ began on April 7, 2025, following initial distribution and prescription filling [10][12] Corporate Developments - Fortress Biotech's subsidiary Journey Medical was added to the small-cap Russell 2000 Index and the broad-market Russell 3000 Index as of June 27, 2025 [8]

DENVER, Aug. 14, 2025 (GLOBE NEWSWIRE) -- authID® (Nasdaq: AUID) (“authID” or the “Company”), a leading provider of biometric identity verification and authentication solutions, today reported financial and operating results for the second quarter ended June 30, 2025. Second Quarter 2025 vs. Second Quarter 2024 Financial Summary Total revenue for the quarter increased significantly to a record $1.4 million, compared to $0.3 million a year ago.Operating expenses were $5.9 million, compared to $3.6 million a ...

Tanruprubart (formerly ANX005) for GBS Advancing Through Regulatory Interactions; MAA Submission in Europe Anticipated in First Quarter of 2026; Ongoing Discussions with FDA Regarding Generalizability Package to Support a BLA Accelerated Completion of Enrollment for Global Phase 3 ARCHER II Trial of Vonaprument (formerly ANX007) for Dry AMD with GA; Selected for EMA PRIME Product Development Candidate Pilot; Topline ARCHER II Data Expected in Second Half of 2026 ANX1502 First-in-Kind Oral C1s Inhibitor Expo ...

Trust Stamp announced that it filed its 2025 Q2 10-Q after the Nasdaq market closed on August 14th, 2025, together with announcing strong growth in customer enrollment and user completions on its SaaS Orchestration LayerAtlanta, GA, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Trust Stamp (Nasdaq: IDAI) announced that: It filed its Q2 10-Q report for the six months ended 30 June 2025 after the Nasdaq market closed on August 14th, 2025. Net recognised revenue for the three months ended 30 June 2025 was $0.81 million, ...

Core Viewpoint - AmpliTech Group, Inc. reported record sales exceeding $11 million for Q2 2025, marking the highest quarterly sales in the company's history, and emphasized a strategic investment approach to secure long-term positions in high-growth sectors such as ORAN 5G networks, quantum computing, and satellite communications [1][6][12] Financial Performance - The company achieved sales of over $11 million in Q2 2025, surpassing total sales for the entire fiscal year 2024 [6] - Despite lower gross profit margins in Q2 2025 due to one-time costs associated with rapid product delivery, management expects regular gross margins to be achievable over the next six months [6][12] - Cash and cash equivalents as of June 30, 2025, were $16,423,238, with working capital of $16,163,710 and no long-term debt [6] - Revenue growth for FY 2025 is projected to exceed 100% year-over-year, with guidance increased to at least $24 million, representing a 140% increase over FY 2024 [12] Strategic Outlook - AmpliTech's focus on ORAN 5G networks, quantum computing, and satellite connectivity is expected to drive significant growth, with ORAN 5G infrastructure projected to reach over $42 billion globally by 2030 [4][7] - The company is uniquely positioned as the only U.S.-based provider of complete, vertically integrated networking solutions, which is expected to enhance its growth trajectory amid increasing demand for secure communications equipment [5][8] - Management believes that the strategy of accelerated market penetration and recurring follow-on orders will establish AmpliTech's products as embedded solutions in next-generation infrastructure [4][8] Market Position - AmpliTech's ORAN 5G radios are recognized as the largest deployment of their kind globally, positioning the company as a leader in the ORAN radio products market [11] - The company’s MMIC LNA modules and LNBs are expected to see growing demand as U.S. and allied nations transition away from foreign component suppliers, creating additional revenue streams with strong margin potential [8][11]

Core Viewpoint - Tevogen Bio Holdings Inc. emphasizes its asset-rich status and plans to disclose a comprehensive inventory of its internally developed assets, which are not reflected in financial reports due to US GAAP accounting rules [2][3]. Company Overview - Tevogen possesses a significant portfolio of intangible assets, including intellectual property, drug development platforms, and proprietary artificial intelligence technology, all of which are fully protected and wholly owned by the company [3]. - The company has a strong insider ownership of 74%, indicating a commitment from its lead investor and a focus on long-term shareholder interests [3]. Future Plans and Expectations - Tevogen aims to advance its research and manufacturing capabilities, with expectations for future growth in the healthcare and biopharmaceutical industries [4]. - The company is focused on developing product candidates for the treatment of infectious diseases and cancer, highlighting its strategic direction [4].

Core Viewpoint - Surge Copper Corp. is advancing its 2025 field program at the Berg copper-molybdenum-precious metals project, focusing on resource updates and a pre-feasibility study while also engaging in a strategic private placement to raise approximately $4.5 million [1][6][7]. Operational Update - The 2025 field program at the Berg project is progressing with resource drilling nearing completion, totaling approximately 1,500 meters planned [2][3]. - The first geotechnical hole has been completed, which will help characterize ground conditions for proposed infrastructure [3]. - The program includes the first uphill-angle drilling at Berg, with a successful 456-meter hole completed at a 14-degree dip to assess mineralization and acid rock drainage potential [4]. - Additional activities include geophysical surveys, environmental baseline studies, and logistical preparations, contributing to the data needed for the pre-feasibility study [5]. Strategic Investment Update - Surge is conducting a private placement of common shares to a strategic investor, increasing their ownership to 19.9% of the company, expected to raise approximately $4.5 million [6][7]. - The subscription agreement for the private placement has been executed, and regulatory approval processes are underway in South Africa [7]. - The transaction is anticipated to close within approximately four weeks, pending necessary regulatory approvals [7]. Upcoming Investor Events - Surge management will participate in several investor conferences in North America and the UK, including the Precious Metals Summit in Colorado and the Metals Investor Forum in Vancouver [10].